Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

NCT00673231 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1240

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Dapagliflozin
DRUG: Dapagliflozin
DRUG: Dapagliflozin
DRUG: Placebo
DRUG: Dapagliflozin
DRUG: Dapagliflozin

Sponsor

AstraZeneca

Collaborators

[object Object]